Format

Send to

Choose Destination
Med Clin North Am. 2017 Jul;101(4):713-724. doi: 10.1016/j.mcna.2017.03.004.

Aspirin for Primary Prevention.

Author information

1
Department of Medicine, Yale University School of Medicine, 367 Cedar Street, Harkness Hall A, Room 301, New Haven, CT 06510, USA. Electronic address: ilana.richman@yale.edu.
2
VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Medicine, Stanford University School of Medicine, Center for Primary Care and Outcomes Research/Center for Health Policy, 117 Encina Commons, Stanford, CA 94305, USA.

Abstract

Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and intracranial bleeding. The best available evidence supports initiating aspirin in select populations. In 2016, the US Preventive Services Task Force recommended initiating aspirin for the primary prevention of both cardiovascular disease and colorectal cancer among adults ages 50 to 59 who are at increased risk for cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular disease risk may also benefit. There remains considerable uncertainty about whether younger and older patients may benefit.

KEYWORDS:

Aspirin; Cardiovascular disease prevention; Colorectal cancer prevention; Guidelines

PMID:
28577622
DOI:
10.1016/j.mcna.2017.03.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center